Apollomics Class A Stock Performance
| APLM Stock | 19.30 0.60 3.21% |
On a scale of 0 to 100, Apollomics holds a performance score of 5. The firm shows a Beta (market volatility) of -2.53, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Apollomics are expected to decrease by larger amounts. On the other hand, during market turmoil, Apollomics is expected to outperform it. Please check Apollomics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Apollomics' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Apollomics Class A are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Apollomics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.24 | Five Day Return (5.58) | Ten Year Return (98.05) | All Time Return (98.05) |
Last Split Factor 1:100 | Last Split Date 2024-11-25 |
1 | Nasdaq to resume trading of Apollomics shares after month-long halt - Investing.com India | 10/14/2025 |
2 | Volume spikes in Apollomics Inc. stock what they mean - July 2025 Decliners Community Trade Idea Sharing Platform - newser.com | 10/31/2025 |
3 | Can Apollomics Inc. Equity Warrant stock resist sector downturns - Trade Exit Summary Short-Term High Return Ideas - newser.com | 11/05/2025 |
4 | Apollomics appoints Dr. Ya-Chi Huang to board following resignation By Investing.com - Investing.com Australia | 11/17/2025 |
5 | Apollomics Stock Rating Lowered by Wall Street Zen | 12/30/2025 |
| Begin Period Cash Flow | 32.1 M | |
| Total Cashflows From Investing Activities | 6 M |
Apollomics | Build AI portfolio with Apollomics Stock |
Apollomics Relative Risk vs. Return Landscape
If you would invest 1,843 in Apollomics Class A on October 7, 2025 and sell it today you would earn a total of 87.00 from holding Apollomics Class A or generate 4.72% return on investment over 90 days. Apollomics Class A is currently generating 0.8362% in daily expected returns and assumes 13.0016% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Apollomics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apollomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apollomics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Apollomics Class A, and traders can use it to determine the average amount a Apollomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0643
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | APLM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Apollomics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apollomics by adding it to a well-diversified portfolio.
Apollomics Fundamentals Growth
Apollomics Stock prices reflect investors' perceptions of the future prospects and financial health of Apollomics, and Apollomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apollomics Stock performance.
| Return On Equity | -2.34 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | 10.07 % | ||||
| Current Valuation | 40.02 M | ||||
| Shares Outstanding | 2.14 M | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 5.97 X | ||||
| Revenue | 198 K | ||||
| Gross Profit | 198 K | ||||
| EBITDA | (41.05 M) | ||||
| Net Income | (53.86 M) | ||||
| Total Debt | 966 K | ||||
| Book Value Per Share | 4.41 X | ||||
| Cash Flow From Operations | (28.74 M) | ||||
| Earnings Per Share | (52.80) X | ||||
| Market Capitalization | 44.92 M | ||||
| Total Asset | 13.1 M | ||||
| Retained Earnings | (700.82 M) | ||||
| Working Capital | 2.87 M | ||||
About Apollomics Performance
By examining Apollomics' fundamental ratios, stakeholders can obtain critical insights into Apollomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Apollomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.45) | (5.18) | |
| Return On Capital Employed | (8.50) | (8.08) | |
| Return On Assets | (4.73) | (4.49) | |
| Return On Equity | (12.73) | (12.10) |
Things to note about Apollomics Class A performance evaluation
Checking the ongoing alerts about Apollomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apollomics Class A help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apollomics Class A is way too risky over 90 days horizon | |
| Apollomics Class A appears to be risky and price may revert if volatility continues | |
| Apollomics Class A has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 198 K. Net Loss for the year was (53.86 M) with profit before overhead, payroll, taxes, and interest of 198 K. | |
| Apollomics generates negative cash flow from operations | |
| Apollomics Class A has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Apollomics Stock Rating Lowered by Wall Street Zen |
- Analyzing Apollomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apollomics' stock is overvalued or undervalued compared to its peers.
- Examining Apollomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apollomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apollomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apollomics' stock. These opinions can provide insight into Apollomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.